Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Reduced by Bank of New Hampshire

Bank of New Hampshire cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,309 shares of the medical research company’s stock after selling 147 shares during the period. Bank of New Hampshire’s holdings in Thermo Fisher Scientific were worth $681,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in TMO. Bangor Savings Bank boosted its stake in shares of Thermo Fisher Scientific by 6.0% during the 4th quarter. Bangor Savings Bank now owns 334 shares of the medical research company’s stock worth $174,000 after acquiring an additional 19 shares in the last quarter. Oliver Luxxe Assets LLC boosted its stake in shares of Thermo Fisher Scientific by 6.2% during the 4th quarter. Oliver Luxxe Assets LLC now owns 9,461 shares of the medical research company’s stock worth $4,922,000 after acquiring an additional 555 shares in the last quarter. Doliver Advisors LP boosted its stake in shares of Thermo Fisher Scientific by 1.6% during the 4th quarter. Doliver Advisors LP now owns 2,803 shares of the medical research company’s stock worth $1,458,000 after acquiring an additional 44 shares in the last quarter. Kings Path Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 13.1% during the 4th quarter. Kings Path Partners LLC now owns 2,637 shares of the medical research company’s stock worth $1,372,000 after acquiring an additional 306 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Thermo Fisher Scientific by 23.6% during the 4th quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company’s stock worth $28,868,000 after acquiring an additional 10,606 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. The trade was a 13.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. This represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,150 shares of company stock worth $25,954,465. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.4 %

NYSE TMO traded up $12.92 during trading on Tuesday, hitting $550.11. 227,464 shares of the company traded hands, compared to its average volume of 1,376,225. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The business has a fifty day simple moving average of $530.39 and a 200 day simple moving average of $568.53. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $210.42 billion, a P/E ratio of 34.49, a PEG ratio of 3.54 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm’s revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the company posted $5.69 earnings per share. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific announced that its board has authorized a share buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is presently 9.78%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TMO shares. Bank of America reduced their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a “buy” rating and a $680.00 target price for the company. StockNews.com cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday. Morgan Stanley raised their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $650.05.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.